Member Info for pomander

I don't know- it just seems strange that they appeared to rush through the creattion of the share scheme immediately post the RP acquisition of Plethora but no options have been granted under it - yet. Originally I thought linked to a possbile takeover as would prevent Dr Mike being conflicted. Anyway, looks like a more solid base being established now, ahead of the EU launch - normally would expect a proportion of investors/traders to get in ahead of the actual launch.Otherwise difficult to understand yesterdays volume spike.

Dr Mike has never joined the Board of RP following the aquisition of Ple in March 2016 ? Dr. Michael G Wyllie, the scientist behind Viagra and Fortacin�, joins Regent Pacific management as Chief Scientific Officer of Plethora and will join the board as an executive director at a later date

As always - top sniffing !

Bignose - any reason why you are expecting profit warning earlier this year ? 24th Feb last year ? I thought 4million was per terrirtory (5 x 800,000) and on first sale, although does not make much difference unless you buy the restricted launch theory, which I don't.

correction - 4th April - JG resigns - 6th April Bignose appointed CEO & first Silo full

4th April - JG resigns, 6th April JM talks him back on board

Pikey - depends upon your definition of clever - are you are a multi millionaire ? Or perhaps ensuring good health and happiness is really clever.

Business model meant to be a lomg term pharma investment company paying healthy didvidends - no sign of that yet- all eggs in one basket here.

I think the pound might be irrelavant now and hopefully if the share price performs like we hope so will the other currencies. Do we have investors or traders ?

Of course a 207% depreciation of the US$ would be handy to erase the profit warning, but that might be beyond even the Don.

Earmings in Euro's which is weak so not good , but conversion of HK$ to � is good as � is weak. Don't they pretty much offset ? Wonder how many weak �19.99 tins have left the shelves over the holidays.

GMCC- Should have read Summit 'Board' - unlike some I don't have unlimited time on my hands so pease forgive the error, although it should have been obvious to anyone that had checked the facts.Its in the announcement. Seems you and your merry men have also left your sense of humours behind - I guess partly understandable holding this stock for 5 years. It was a heads up to the trolly dolly to get over to the US and remove those awful trolls that are short and posting negative comments. Of course the short interest is not huge a small cap- almost impossible to borrow in scale and HF's not interested so left to RP's via CFD's, SB's etc. I think Discuva is another corporate strategy blip, just as was failing to leverage on the opprtunity when Sum was hot, several years back now and the pharma sector was bubbling up, to raise funds and a partner, instead tried to go it alone which was a mistake , and one made by many a small pharma company - all in my humble opinion of course Its history anyway except that it brings management into question just as it did for II's when they voted down the proposed executive remuneration policy.

Wow - a new Cambridge address, now that really is one critical success factor to tick off. As for new staff, seems to me the key staff have gone, as former employees remain entitled under the Roche agreement and no members of Discuva have joined the Summit. I am just surprised the trolly dolly has time to post his nonsense with so many punters across the pond holding short positions in Summit for him to chase down in addition to the washing-up duities at home to take care off.

Mr Mac - Whilst I certainly hope you are right and if you are, it does beg the question as to why Discuva sold out now, for a pretty paltry $5m and 50% of the income sharing arrangement with Roche and made its staff redundant in teh process. I know it also received Sunmmit shares, but they don't have a guaranteed future value. I wonder why they could not raise funding directly from Roche or indeed attract pharma interest in light of your view on the antibiotic market generally. I do hope its not an exponentially growing market as the world will quickly become a very sick place !

Teacups, but at least daily volumes are elevated, indicating greater interest, which will hopefully climax in early March !

I am afraid that is wishful tinking at this time Mr Mac.Big Pharma has basically given up on antibiotics. It�s not that the risks are too high, it is that the rewards are too low. New antibiotics are being introduced, but their sales are a tiny fraction of sales in other drug classes. If you were to present the FDA with a novel antibiotic that is effective against all multi-drug resistant organisms currently known, the FDA�for excellent reasons�would want to approve it only for the narrow indication of third-line treatment of multi-drug resistant infections. In this way, it would remain useful longest, but this can not work and is commericially unattractive.. Long before the patent protection had expired, a pirate company (historic precedent suggests in India) would be producing it, and selling it, and�inevitably, it seems�a resistant infection would defeat it long before you made back the huge costs of R&D. There needs to be a complete structural change in approach and whilst Governmenet incentives of various kinds are being introduced they have yet to gain meaningful traction on a scale to defeat what is unquestinably a huge and dangerous problem facing mankind.

Bingnoe - My default position is laways to try and logic to these situations, but this stocks trading pattern seems to defy all logic. The huge volumes post the EU launch (3 billion in a few weeks) should have began at some level well ahead of the actual launch date following its announcement; it was well known about months in advance. There was no price action or volumes leading up to the launch as one would expect from traders taking a position, instead we got an explosion in volumes (3 billion) in a few weeks following the launch. It was if the UK launch triggered something for certain interested parties immediately post the launch. In regard to the announcement of the EU launch I would have expected much higher volumes than we have seen. It is the most significant event for the company to date. It is therefore difficult for me to believe that traders are savvy enough to be aware or concerned about what is a pretty meaningless accounting generated likely profits warning whilst in the past they have not reacted sooner to announcements about both the UK and the EU launch, rather waiting for them to happen. You are always behind the curve adopting that approach. The only logical conclusion for me is that at this point in time, (assuming the wider investment community is aware of RP/Fortacin) is that they do not view Fortacin as the commercially attractive opportunity that the company projections predict. It could all turn very quickly.

Bignose - tehre is always teh argumnet that the EU launch is already in the price. I think raising awareness to a wider shareholder base , partcallrly institutions to take long term stakes is key. Volumes post UK launch still make no sense if just down to traders.

Should of known that you would have all bases covered !

Blimey - a supporter of AIM. I am happy with the HKSE listing, massive market compared to AIM, when the wall of money farrives, I expect a tsunami that will take out Bignose's silo. Difficult for me to judge HK broker coverage as feel somewhat disconnected to what might be going on over there.